HighTower Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

HighTower Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$865K	Buy	37,031 +18,091	+96%	+$393K	﹤0.01%	2289
2025 Q4	$398K	Buy	18,940 +1,517	+9%	+$26.5K	﹤0.01%	2815
2025 Q3	$268K	Buy	+17,423	New	+$228K	﹤0.01%	3137
2021 Q4	–	Sell	-10,741	Closed	-$207K	–	3465
2021 Q3	$207K	Buy	+10,741	New	+$179K	﹤0.01%	2686

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

HighTower Advisors's SNDX Position: Q1 2026 in Review

HighTower Advisors increased its Syndax Pharmaceuticals (SNDX) stake by 96% in Q1 2026, buying an estimated $393K and bringing the position to 37,031 shares worth $865K. The position accounts for ﹤0.01% of the portfolio, ranked #2289.

HighTower Advisors first reported a position in SNDX in Q3 2021 and has held it in 4 quarters since. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

HighTower Advisors held 37,031 shares of Syndax Pharmaceuticals worth $865K as of Q1 2026.
HighTower Advisors bought 18,091 Syndax Pharmaceuticals shares in Q1 2026, an estimated $393K.
Syndax Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #2289 holding.
HighTower Advisors first reported a position in Syndax Pharmaceuticals in Q3 2021 and has held it in 4 quarters since.
246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.